Divi’s Laboratories Q4 Results: Divi’s Laboratories announced its January-March quarter results for fiscal 2023-24 (Q4FY24) on Saturday, May 25, reporting a rise of 67.6 per cent in net profit at ₹538 crore, compared to ₹321 crore in the corresponding period last year.
The pharma major’s revenue from operations in the fourth quarter of FY24 rose 18 per cent to ₹2,303 crore, compared to ₹1,951 crore in the year-ago period. The company’s board also recommended a final dividend of 1,500 per cent i.e., at ₹30 per equity share for the face value of ₹2 each for fiscal ended March 31, 2024.
The dividend is subject to the approval of the company’s shareholders. The company’s 34th annual general meeting (AGM) will be held on August 12, 2024. The record date for the purpose of the payment of dividend is August 2, 2024.
At the operating level, Divi’s Labs earnings before interest, tax, depreciation and amortization (EBITDA) in the March quarter rose 50.1 per cent to ₹731 crore, compared to ₹487 crore in the same period last year. Margin rose to 32 per cent compared to 25 per cent in the year-ago period.
The Hyderabad-based multinational pharma company is a producer of active pharmaceutical ingredients, custom synthesizes generic APIs and intermediates. According to the latest BSE rejig, Divi’s Laboratories will be added to the Sensex Next 50 index. On Friday, shares of Divi’s Laboratory settled 0.30 per cent higher at ₹4,122.75 apiece on the BSE.
You are on Mint! India’s #1 news destination (Source: Press Gazette). To learn more about our business coverage and market insights Click Here!
Download The Mint News App to get Daily Market Updates & Live Business News.
Published: 25 May 2024, 04:21 PM IST
 "India reiterates opposition to China’s Belt and Road Initiative at SCO meet | External Affairs Defence Security News")
 "Trade deficit eases to $20.8 bn in Sept amid geopolitical challenges | Economy & Policy News")
